NovaBay Pharmaceuticals Inc
NovaBay Pharmaceuticals, Inc. manufactures and sells wound care products. The company offers hypochlorous acid for use in the cleansing and irrigation of post-surgical wounds, minor burns, and superficial abrasions. It sells its products to its distribution partners in China. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in F… Read more
NovaBay Pharmaceuticals Inc (NBY) - Total Liabilities
Latest total liabilities as of September 2025: $1.85 Million USD
Based on the latest financial reports, NovaBay Pharmaceuticals Inc (NBY) has total liabilities worth $1.85 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
NovaBay Pharmaceuticals Inc - Total Liabilities Trend (2003–2024)
This chart illustrates how NovaBay Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
NovaBay Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of NovaBay Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
VSBLTY Groupe Technologies Corp
PINK:VSBGF
|
USA | $10.75 Million |
|
Elemental Royalties Corp
OTCQX:ELEMF
|
USA | $4.04 Million |
|
Aethlon Medical Inc
NASDAQ:AEMD
|
USA | $1.34 Billion |
|
NETCLASS TECHNOLOGY INC Class A Ordinary Shares
NASDAQ:NTCL
|
USA | $7.83 Million |
|
iMetal Resources Inc.
OTCQB:IMRFF
|
USA | $1.10 Million |
|
GENRF
OTCGREY:GENRF
|
USA | $122.12K |
Liability Composition Analysis (2003–2024)
This chart breaks down NovaBay Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.00 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 1.59 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.13 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.53 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how NovaBay Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for NovaBay Pharmaceuticals Inc (2003–2024)
The table below shows the annual total liabilities of NovaBay Pharmaceuticals Inc from 2003 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $3.55 Million | -37.90% |
| 2023-12-31 | $5.72 Million | -2.14% |
| 2022-12-31 | $5.84 Million | -57.67% |
| 2021-12-31 | $13.81 Million | +372.84% |
| 2020-12-31 | $2.92 Million | -71.50% |
| 2019-12-31 | $10.25 Million | +132.52% |
| 2018-12-31 | $4.41 Million | -41.12% |
| 2017-12-31 | $7.49 Million | -9.60% |
| 2016-12-31 | $8.28 Million | -18.62% |
| 2015-12-31 | $10.18 Million | +78.85% |
| 2014-12-31 | $5.69 Million | -20.26% |
| 2013-12-31 | $7.13 Million | +37.56% |
| 2012-12-31 | $5.19 Million | -21.65% |
| 2011-12-31 | $6.62 Million | +31.70% |
| 2010-12-31 | $5.03 Million | +20.30% |
| 2009-12-31 | $4.18 Million | -36.93% |
| 2008-12-31 | $6.62 Million | -31.01% |
| 2007-12-31 | $9.60 Million | -4.49% |
| 2006-12-31 | $10.05 Million | +3142.90% |
| 2005-12-31 | $310.00K | -39.57% |
| 2003-12-31 | $513.00K | -- |